UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 118

Sortiert nach

Death receptor agonist therapies for cancer, which is the right TRAIL?

Cytokine & growth factor reviews, 2014-04, Vol.25 (2), p.185-193

Holland, Pamela M

2014

Volltextzugriff (PDF)

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

Journal for immunotherapy of cancer, 2020-04, Vol.8 (1), p.e000413

2020

Volltextzugriff (PDF)

Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL

Cancer letters, 2013-05, Vol.332 (2), p.156-162

Holland, Pamela M

2013

Volltextzugriff (PDF)

Therapeutic potential of cis-targeting bispecific antibodies

Cell chemical biology, 2024-08

2024

Volltextzugriff (PDF)

Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases

Arthritis & rheumatology (Hoboken, N.J.), 2023-07, Vol.75 (7), p.1187-1202

2023

Volltextzugriff (PDF)

Non‐Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN‐101)

Arthritis & rheumatology (Hoboken, N.J.), 2023-08, Vol.75 (8), p.1344-1356

2023

Volltextzugriff (PDF)

Abstract 4548: SRF813, a fully human monoclonal antibody targeting the inhibitory receptor CD112R, enhances immune cell activation and demonstrates preclinical in vivo anti-tumor activity

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4548-4548

2020

Volltextzugriff (PDF)

Abstract 1802: CD39 inhibition shapes the transcriptional landscape of myeloid cells and induces proinflammatory states in the CT26 syngeneic tumor model

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1802-1802

2021

Volltextzugriff (PDF)

Abstract 6639: SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.6639-6639

2020

Volltextzugriff (PDF)

Abstract 4550: Increased IL-27 is associated with poor prognosis in renal cell carcinoma and supports use of SRF388, a first-in-class IL-27p28 blocking antibody, to counteract IL-27-mediated immunosuppression in this setting

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4550-4550

2020

Volltextzugriff (PDF)

Abstract 558: MERTK-specific antibodies that have therapeutic antitumor activity in mice disrupt the integrity of the retinal pigmented epithelium in cynomolgus monkeys

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.558-558

2019

Volltextzugriff (PDF)

The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

Blood, 2018-11, Vol.132 (Supplement 1), p.4393-4393

2018

Volltextzugriff (PDF)

Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas

Blood, 2018-11, Vol.132 (Supplement 1), p.339-339

2018

Volltextzugriff (PDF)

CD47 Monoclonal Antibody SRF231 Is a Potent Inducer of Macrophage-Mediated Tumor Cell Phagocytosis and Reduces Tumor Burden in Murine Models of Hematologic Malignancies

Blood, 2016-12, Vol.128 (22), p.1843-1843

2016

Volltextzugriff (PDF)

Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

Journal for immunotherapy of cancer, 2020-04, Vol.8 (1), p.e000878corr1

2020

Volltextzugriff (PDF)

Correction: Metastatic breast cancers have reduced immune cell recruitment but harbour increased macrophages relative to their matched primary tumors

Journal for immunotherapy of cancer, 2020-04, Vol.8 (1), p.e0755-1corr1

2020

Volltextzugriff (PDF)

Correction: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers

Journal for immunotherapy of cancer, 2020-04, Vol.8 (1), p.e0737-3corr1

2020

Volltextzugriff (PDF)

Detection of Specific Polymerase Chain Reaction Product by Utilizing the 5' → 3' Exonuclease Activity of Thermus aquaticus DNA Polymerase

Proceedings of the National Academy of Sciences - PNAS, 1991-08, Vol.88 (16), p.7276-7280

1991

Volltextzugriff (PDF)

Targeting Apoptosis Pathways

Targeted Therapies in Oncology, 2014, p.271-300

2014

Volltextzugriff (PDF)

NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome

Proceedings of the National Academy of Sciences - PNAS, 2013-02, Vol.110 (8), p.2952-2956

2013

Volltextzugriff (PDF)

Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease

Annals of the American Thoracic Society, 2014-01, Vol.11 (1), p.30-35

2014

Volltextzugriff (PDF)

Challenges to curing primary brain tumours

Nature reviews. Clinical oncology, 2019-08, Vol.16 (8), p.509-520

2019

Volltextzugriff (PDF)

Distinct CRTH2+CD161+ (peTh2) memory CD4+ T-cell cytokine profiles in food allergy and eosinophilic gastrointestinal disorders

Clinical and experimental allergy, 2023-10, Vol.53 (10), p.1031-1040

2023

Volltextzugriff (PDF)

1 – 25 von 118

Suche als RSS-Feed

Aktive Filter

ThemaAnimals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(115)
Mit Volltextzugriff
(100)

Publikationsform

Artikel
(117)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Death receptor agonist therapies for cancer, which is the right TRAIL?

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL

Therapeutic potential of cis-targeting bispecific antibodies

Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell–Related Autoimmune Diseases

Non‐Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN‐101)

Abstract 4548: SRF813, a fully human monoclonal antibody targeting the inhibitory receptor CD112R, enhances immune cell activation and demonstrates preclinical in vivo anti-tumor activity

Abstract 1802: CD39 inhibition shapes the transcriptional landscape of myeloid cells and induces proinflammatory states in the CT26 syngeneic tumor model

Abstract 6639: SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies

Abstract 4550: Increased IL-27 is associated with poor prognosis in renal cell carcinoma and supports use of SRF388, a first-in-class IL-27p28 blocking antibody, to counteract IL-27-mediated immunosuppression in this setting

Abstract 558: MERTK-specific antibodies that have therapeutic antitumor activity in mice disrupt the integrity of the retinal pigmented epithelium in cynomolgus monkeys

The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax

Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas

CD47 Monoclonal Antibody SRF231 Is a Potent Inducer of Macrophage-Mediated Tumor Cell Phagocytosis and Reduces Tumor Burden in Murine Models of Hematologic Malignancies

Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

Correction: Metastatic breast cancers have reduced immune cell recruitment but harbour increased macrophages relative to their matched primary tumors

Correction: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers

Detection of Specific Polymerase Chain Reaction Product by Utilizing the 5' → 3' Exonuclease Activity of Thermus aquaticus DNA Polymerase

Targeting Apoptosis Pathways

GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity

NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome

Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease

Challenges to curing primary brain tumours

Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency

Distinct CRTH2+CD161+ (peTh2) memory CD4+ T-cell cytokine profiles in food allergy and eosinophilic gastrointestinal disorders

Aktive Filter

Suchergebnisse filtern